SCHEMBL5433798

SCHEMBL5433798

O=C(O)c1ccc2c(c1)c(C1CCCC1)c(-c1ccccc1)n2CC(=O)N1CCC(N2CCCC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
TSHR P16473 1/20 0.49
CDYL2 Q8N8U2 5/20 0.46
CDYL Q9Y232 5/20 0.46
CBX7 O95931 4/20 0.46
CDY1; CDY1B Q9Y6F8 3/20 0.46
L3MBTL3 Q96JM7 7/20 0.45
L3MBTL1 Q9Y468 6/20 0.43
ACHE P22303 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 1/20 0.43
HRH3 Q9Y5N1 1/20 0.40
MBTD1 Q05BQ5 2/20 0.39
TP53BP1 Q12888 1/20 0.39
L3MBTL4 Q8NA19 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5448433 0.93 POLB (0.49) POLBGAATSHRCDYL2CDYL
SCHEMBL12871485 0.88 CDYL2 (0.42) POLBGAATSHRCDYL2CDYL
SCHEMBL5444173 0.86 AKR1B10 (0.37) POLBGAATSHRNPSR1HTT
SCHEMBL5444178 0.86 CNR2 (0.40) TSHRNPSR1HTTCNR2
SCHEMBL5402763 0.84 CYP2C9 (0.43) POLBGAATSHRCDYL2CDYL
SCHEMBL5445772 0.82 CBX7 (0.49) POLBGAATSHRCDYL2CDYL
SCHEMBL5398126 0.81 SCN9A (0.46) POLBGAATSHRCDYL2CDYL
SCHEMBL5435153 0.81 HTT (0.43) POLBGAATSHRNPSR1HTT
SCHEMBL5442463 0.81 CBX7 (0.47) POLBGAATSHRCDYL2CDYL
SCHEMBL2909117 0.79 PRKCA (0.44) POLBGAATSHRNPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167447-A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) 2007-07-19 US claimed
JP-2007516158-A 2007-06-21 JP claimed
EP-1613634-A1 INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2006-01-11 EP claimed
WO-2004087714-A1 INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2004-10-14 WO claimed
US-20070167447-A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) 2007-07-19 US disclosed
US-20070167447-A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) 2007-07-19 US disclosed
US-20070167447-A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) 2007-07-19 US disclosed
EP-1613634-A1 INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2006-01-11 EP disclosed
WO-2004087714-A1 INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167447-A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase IDO1, NAT1, AANAT POLB 2000/4885GAA 3242/4885TSHR 2555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.